This trial is testing the impact of an invention for early detection of skin cancer in stem cell transplant survivors and their primary care providers.
- Skin Cancer
6 Primary · 0 Secondary · Reporting Duration: Up to 12 months
3 Treatment Groups
Group III (PAE, physician, dermatoscope)
1 of 3
Group I (PAE)
1 of 3
Group II (PAE, physician)
1 of 3
720 Total Participants · 3 Treatment Groups
Primary Treatment: Dermatoscope · No Placebo Group · N/A
Who is running the clinical trial?
Age 18+ · All Participants · 6 Total Inclusion CriteriaMark “Yes” if the following statements are true for you:
- Armenian, Saro H., Lanie Lindenfeld, Aleksi Iukuridze, Meagan Echevarria, Samantha Bebel, Catherine Coleman, Ryotaro Nakamura, et al.. 2020. “Technology-enabled Activation of Skin Cancer Screening for Hematopoietic Cell Transplantation Survivors and Their Primary Care Providers (TEACH)”. BMC Cancer. Springer Science and Business Media LLC. doi:10.1186/s12885-020-07232-2.
- 2020. "Technology-Enabled Activation of Skin Cancer Screening for Stem Cell Transplant Survivors and Their Primary Care Providers, TEACH Study". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04358276.
Frequently Asked Questions
How many individuals have been recruited to take part in this experiment?
"Indeed, the clinicaltrials.gov database suggests that this research is actively looking for volunteers. The trial was initially published on October 30th 2020 and its information has since been updated on May 23rd 2022. 720 participants are needed from a single site to fulfill their quota." - Anonymous Online Contributor
Is there currently a call for volunteers for this research project?
"Affirmative, clinicaltrials.gov attests to the ongoing recruitment for this trial which was inaugurated on October 30th 2020 and most recently refreshed on May 23rd 2022. To date, a total of 720 patients have need to be enrolled from 1 medical facility." - Anonymous Online Contributor